The first patients were treated at the Leon Berard Center in Lyon, France, by principal investigator Dr. Pascal Pommier and colleagues, according to the company. The trial is currently being conducted at six cancer centers in France on patients with malignant cutaneous lesions, including squamous cell carcinoma, basal cell carcinoma, lentigo maligna melanoma, and carcinosarcoma.
It will include 36 patients with locally recurrent disease and up to 49 patients newly diagnosed with skin cancer. The trial's primary effectiveness endpoint is the overall response rate nine to 11 weeks after Alpha DaRT source insertion, Alpha Tau said.
Copyright © 2022 AuntMinnieEurope.com